Overview
Background
Associate Professor Melissa Eastgate is the Operation Director of Cancer Care Services at the RBWH, acting stream lead Metro North HHS Cancer Care Services and has acted as the Executive Director of Cancer Care Services. Melissa is the current Chair of the Medical Oncology Group of Australia. Melissa completed her medical degree at the University of Queensland and gained her FRACP in Medical Onoclogy in 2004. Since then she has worked at the RBWH as a medical oncologist, with her main clinical interests being melanoma and gastrointestinal cancers, in which areas she is an active researcher. Melissa established the Melanoma MDT at the RBWH. Melissa supervises physician trainees throughout their training and is the previous Chair of the RACP Advanced Training Committee for Medical Oncology. Melissa has a strong interest in enabling access to care for patients, having provided outreach services to Bundaberg for nine years, and currently is the medical lead of the Telechemotherapy service in Longreach and Barcaldine.
Availability
- Associate Professor Melissa Eastgate is:
- Available for supervision
Research interests
-
Management of metastatic melanoma
-
Management of gastrointestinal cancers
-
Medical oncology training
Works
Search Professor Melissa Eastgate’s works on UQ eSpace
2025
Journal Article
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis
Sangro, Bruno, Bouattour, Mohamed, Park, Joong-Won, Diaz, Dr. Consuelo, Erinjeri, Joseph P., Alves, Gustavo Vasconcelos, Gu, Shan-Zhi, Manikhas, Aleksei, Kuroda, Hidekatsu, Suksombooncharoen, Thatthan, Vo, Truc Hoi Trung, Ostwal, Vikas S., Eastgate, Melissa A., Vaccaro, Gina M., Griffin, Rebecca, Ali, Sajid, Balaji, Kavitha and Chan, Stephen Lam (2025). Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis. Journal of Clinical Oncology, 43 (4_suppl), 574-574. doi: 10.1200/jco.2025.43.4_suppl.574
2025
Journal Article
Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia
Xia, Qing, Senanayake, Sameera Jayan, Kularatna, Sanjeewa, Brain, David, McPhail, Steven M., Parsonage, Will, Eastgate, Melissa, Barnes, Annette, Brown, Nick and Carter, Hannah E. (2025). Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia. Urologic Oncology, 43 (1), 62.e15-62.e26. doi: 10.1016/j.urolonc.2024.09.016
2024
Conference Publication
Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study
Sim, H-W., McLachlan, S-A., Dean, A., Price, T.J., Eastgate, M., Rimassa, L., Mercade, T. Macarulla, Malka, D., Gharbi, H., Robert, R., Sullivan, A. and Vogel, A. (2024). Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study. ESMO Asia Congress 2024, Singapore, 6 – 8 December 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.10.171
2024
Journal Article
Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled Trial
Hapgood, Greg, Hill, Kate, Okano, Satomi, Abro, Emad, Looke, David, Kennedy, Glen, Pavilion, Gilbert, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa, Jones, Mark and Mollee, Peter (2024). Catheter-Related Thrombosis in Adults with Cancer: A Secondary Analysis of a Prospective Randomised Controlled Trial. Journal of Thrombosis and Haemostasis, 23 (2), 627-634. doi: 10.1016/j.jtha.2024.11.002
2024
Journal Article
Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer
Webb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836
2024
Journal Article
Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial
Boyte, M. Francesca, Scanlon, Gradcert Brighid, Matthews, Robyn, Button, Elise, Jones, Lee, Hayes, Therese, Partridge, Grant, Smith, Michael, Kennedy, Glen Andrew, Eastgate, Melissa and Gavin, Nicole Clare (2024). Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial. Clinical Journal of Oncology Nursing, 28 (5), E9-E15. doi: 10.1188/24.CJON.E9-E15
2024
Conference Publication
Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial
Nalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121
2024
Journal Article
Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol
Matthews, Robyn, Russell, Emily, Wessling, Claire, Sandler, Carolina, Eastgate, Melissa, Hajkowicz, Krispin, Pavey, Toby, Clark, Bronwyn K., Scanlon, Brighid and Gavan, Nicole C. (2024). Exploring the administration of intravenous antibiotics and fluids via portable intravenous pump versus intravenous pump and pole to improve mobility in patients diagnosed with cancer (The ACTIVE Trial): A randomized controlled trial protocol. Vascular Access Journal of the Canadian Vascular Access Association, 18 (2), 44-58. doi: 10.5737/va.v18.i2.44
2023
Conference Publication
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma
Lau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A. and Sandhu, Shahneen (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.9525
2023
Conference Publication
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO
Day, Fiona, Sridharan, Swetha, Michael, Michael, Christophersen, Louise, Moore, Melissa M., Eastgate, Melissa A., Thompson, Stephen, MWEEMPWA, ANGELA, Oldmeadow, Christopher, Fraser, Allison and Martin, Jarad (2023). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps4172
2023
Journal Article
Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer
Lee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091
2022
Conference Publication
A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors
Khushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F. and Ascierto, P. (2022). A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. ESMO Asia Congress 2022, Singapore, 2-4 December 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.10.052
2022
Conference Publication
Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospital
Turner, Cassie L. and Eastgate, Melissa (2022). Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospital. HOBOKEN: WILEY.
2022
Journal Article
Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis
Pathmanathan, Shivanshan, Babu, Hari, Dzienis, Marcin, Azer, Mary and Eastgate, Melissa (2022). Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis. Pigment Cell and Melanoma Research, 35 (6), 587-594. doi: 10.1111/pcmr.13063
2022
Conference Publication
Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting
Kim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY.
2022
Conference Publication
Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D., Starus, A., Lamik, A., Sieber, O., Begbie, S., Bonaventura, A., Rai, S., Karanth, N., Underhill, C. R., Nott, L. M., Van Hazel, G., Van Hagen, T., Wong, M., Saqib, A., Eastgate, M., Srivastav, R., Chia, J., Toh, H. C., Jones, F. and Segelov, E. (2022). Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Electr Network, Sep 09-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2022.07.518
2022
Conference Publication
Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysis
Pathmanathan, Shivanshan, Babu, Hari S., Dzienis, Marcin Radoslaw, Azer, Mary and Eastgate, Melissa A. (2022). Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2022
Journal Article
Selective targeting of protein kinase C (PKC)-θ nuclear translocation reduces mesenchymal gene signatures and reinvigorates dysfunctional CD8+ T cells in immunotherapy-resistant and metastatic cancers
Dunn, Jenny, McCuaig, Robert D., Tan, Abel H. Y., Tu, Wen Juan, Wu, Fan, Wagstaff, Kylie M., Zafar, Anjum, Ali, Sayed, Diwakar, Himanshu, Dahlstrom, Jane E., Bean, Elaine G., Forwood, Jade K., Tsimbalyuk, Sofiya, Cross, Emily M., Hardy, Kristine, Bain, Amanda L., Ahern, Elizabeth, Dolcetti, Riccardo, Mazzieri, Roberta, Yip, Desmond, Eastgate, Melissa, Malik, Laeeq, Milburn, Peter, Jans, David A. and Rao, Sudha (2022). Selective targeting of protein kinase C (PKC)-θ nuclear translocation reduces mesenchymal gene signatures and reinvigorates dysfunctional CD8+ T cells in immunotherapy-resistant and metastatic cancers. Cancers, 14 (6) 1596, 1596. doi: 10.3390/cancers14061596
2021
Journal Article
Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions
Jones, M., Okano, S., Looke, D., Kennedy, G., Pavilion, G., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M. and Mollee, P. (2021). Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions. Journal of Hospital Infection, 118, 70-76. doi: 10.1016/j.jhin.2021.10.008
2021
Journal Article
The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial
Molassiotis, Alex, Brown, Teresa, Cheng, Hui Lin, Byrnes, Angela, Chan, Raymond Javan, Wyld, David, Eastgate, Melissa, Yates, Patsy, Marshall, Andrea P, Fichera, Rebecca, Isenring, Liz, To, Ki Fung, Ko, Po Shan, Lam, Wang, Lam, Yuk Fong, Au, Lai Fan and Lo, Raymond See-kit (2021). The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial. Nutrition Journal, 20 (1) 2, 2. doi: 10.1186/s12937-020-00657-2
Supervision
Availability
- Associate Professor Melissa Eastgate is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Associate Professor Melissa Eastgate's areas of expertise, story ideas and help finding experts, contact our Media team: